Zheila J. Azartash-Namin

Zheila J. Azartash-Namin

Auto-generated profile, based on publicly available information

Zheila J. Azartash-Namin

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation 1 , Oklahoma City, OK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
XGXin Geng
Xin Geng
LCLijuan Chen
Lijuan Chen
ZAZoheb Ahmed
Zoheb Ahmed
GFGuilherme Pedron Formigari
Guilherme Pedron Formigari
YHYenChun Ho
YenChun Ho
RSR. Sathish Srinivasan
R. Sathish Srinivasan
Efficient lymph flow is ensured by lymphatic valves (LVs). The mechanisms that regulate LV development are incompletely understood. Here, we show that the deletion of the GPCR sphingosine 1-phosphate receptor-1 (S1PR1) from lymphatic endothelial cells (LECs) results in fewer LVs. Interestingly, LVs that remained in the terminal ileum-draining lymphatic vessels were specifically dysfunctional. Furthermore, tertiary lymphoid organs (TLOs) formed in the terminal ileum of the mutant mice. TLOs in this location are associated with ileitis in humans and mice. However, mice lacking S1PR1 did not develop obvious characteristics of ileitis. Mechanistically, S1PR1 regulates shear stress signaling and the expression of the valve-regulatory molecules FOXC2 and connexin-37. Importantly, Foxc2+/− mice, a model for lymphedema-distichiasis syndrome, also develop TLOs in the terminal ileum. Thus, we have discovered S1PR1 as a previously unknown regulator of LV and TLO development. We also suggest that TLOs are a sign of subclinical inflammation that can form due to lymphatic disorders in the absence of ileitis.

8 June 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
KFKylie Foster
Kylie Foster
ABAhmed M El Banayosy
Ahmed M El Banayosy
ZAZheila Azartash-Namin
Zheila Azartash-Namin
PCPhillip Coghill
Phillip Coghill
JLJames W. Long
James W. Long
HSHendra Setiadi
Hendra Setiadi
Implantations of Ventricular Assist Devices (VADs) have significantly improved quality of life and life expectancy of end-stage heart failure patients. However, despite the advancements in the VAD designs and patient management protocols, the VAD recipients remain at risk of attaining bleeding, infection, pump thrombosis, and stroke. Although blood trauma has been suggested as a critical factor in development of these adverse events, its consequences in inducing interactions between different types of blood cells are largely unknown. Following our recent findings on erythrocyte and leukocyte trauma in VAD recipients, we decided to explore interactions between erythrocytes and leukocytes by perfusing human whole blood through two different types of VADs, HeartMate II (HMII) and HeartMate 3 (HM3), concurrently in their respective Blood Circulatory Loop (BCL). By using a flow cytometry assay, we found increasing association between erythrocytes and leukocytes as VADs propelled blood through their BCLs. This time-dependent intercellular association was shown by increasing concomitant events of stained CD235a (specifically expressed on erythrocytes) and stained CD45 (specifically expressed on leukocytes) in the CD235a+ population. Compared to CentriMag (CM), which served as a control, VADs produced significantly higher concomitant signals. The findings described in this study have opened the need for further studies on a novel path for generation of adverse events that are commonly observed in VAD recipients, notably infection, pump thrombosis, and ischemic stroke.